Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 plus gemcitabine in relapsed or refractory osteosarcoma
NL-OMON54108Phase 2Withdrawn
- Sponsor
- K-Group Beta, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azenosertib and gemcitabine in osteosarcoma (OS), sponsored by K-Group Beta, Inc. Primary endpoints: Incidence and severity of dose-limiting toxicities and Event-free survival at 18 weeks. Planned start Jan 2022; status: withdrawn.
02
Drugs
azenosertibgemcitabine
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NL-OMON54108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54108.